Odyssey pulls back from IPO plans as pub­lic mar­kets re­main frozen

Im­munol­o­gy biotech Odyssey Ther­a­peu­tics has with­drawn its plans to go pub­lic via an IPO, ac­cord­ing to a reg­u­la­to­ry fil­ing on Mon­day evening.

The biotech didn’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER